~~<i id='E1FA466522'><strike id='E1FA466522'><tt id='E1FA466522'><pre id='E1FA466522'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：explore 2025-10-02 11:10:16 - browse：54567

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Risky weight loss products often used by teens globally, per study

hotspot

focus

hotspot

explore

focus

5:04InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi

WSS

Caregivers of transplant patients call for more support, training

Hospitals are dialing back on venture capital investing

Hospitals are dialing back on venture capital investing

Idaho college killings prosecutors challenge defense's grand jury claims

Fauci’s Covid grilling leads GOP to weigh foreign research rules

DeSantis can now import cheaper drugs. But will Biden get credit?

knowledge

comprehensive

hotspot

How to save PrEP access — and even expand it

Maui wildfire now ranks as the fifth

ChatGPT in medicine: STAT answers readers' burning questions

Risky weight loss products often used by teens globally, per study

Bright Health sells Medicare Advantage business to Molina

Schizophrenia gene found to be linked to cells' energy dysfunction

Anesthesiologist group: stop taking Ozempic before surgery

Treatments for cramps don't cut it. Why aren't there better options?

In age of alternative facts, a scholarly course on calling out crap

Doulas covered by Medicaid under New York's new plan

hotspot

Readout LOUD podcast: live from JPM 2024

The nurse manager staffing crisis is hurting patients

Judge sides with young activists in first

Patients, digital health players weigh in on FTC's data privacy plan

Maui wildfire now ranks as the fifth

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

focus

hotspot

explore

focus